QIAGEN is expanding its portfolio for QIAstat-Dx in North America, with the recent launch of the QIAstat-Dx Analyzer 2.0, FDA clearance of the Gastrointestinal Panel 2 and submission for FDA clearance ...
Drug screening is the process by which potential drugs are identified and optimized before selection of a candidate drug to progress to clinical trials. It can involve screening large libraries of ...
The panel also had concerns ... with first-quarter sales of the drug recorded at just $19 million, albeit up from $7 million in the fourth quarter and $10 million for 2023 as a whole.
Days after he ruled out the possibility of either Senators Ronald “Bato” dela Rosa or Christopher “Bong” Go heading a Senate inquiry into the drug war killings under the previous ...